A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

Journal article

Peer reviewed

Lee Schwartzberg, Timothy Rearden, Lorrin Yee, Barry Mirtsching, Veena Charu, Hung Lam, Tom Lillie, Ronald Burkes and Peter Silberstein

Journal of Supportive Oncology, Vol.5(4 SUPPL. 2), pp.22-23

5

04/01/2007

Abstract

Oncology

Pharmacology (medical)

4 Record Views

Title: A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia
Creators: Lee Schwartzberg (Author)
Timothy Rearden (Author)
Lorrin Yee (Author)
Barry Mirtsching (Author)
Veena Charu (Author)
Hung Lam (Author)
Tom Lillie (Author)
Ronald Burkes (Author)
Peter Silberstein (Author) - Department of Medicine
Publication Details: Journal of Supportive Oncology, Vol.5(4 SUPPL. 2), pp.22-23
Series: 5
Number of pages: 2
Identifiers: 991005928611902656
Academic Unit: General Medicine
Language: English
Resource Type: Journal article